Seres therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass.--( business wire )--seres therapeutics, inc. (nasdaq: mcrb) (“seres” or the “company”), a leading microbiome therapeutics company, today announced that on february 1, 2023, the compensation and talent committee of seres' board of directors granted inducement equity grants covering an aggregate of 48,750 shares of its common stock to eleven new employees, consisting of stock options to purchase an aggregate of 32,500 shares of common stock and restricted stock units (“rsus”), covering an aggregate of 16,250 shares of its common stock.
MCRB Ratings Summary
MCRB Quant Ranking